NCT01547299View on ClinicalTrials.gov

Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Prostate Cancer
Interventions
DRUG

Enzalutamide

DRUG

Leuprolide

DRUG

Dutasteride

Trial Locations (4)

98195

Seattle

02215

Boston

V5Z 1M9

Vancouver

M5G 2M9

Toronto

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

collaborator

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT01547299 - Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer | Biotech Hunter | Biotech Hunter